NCT05694754

Brief Summary

This study evaluates de efficacy of Theta Burst Transcranial Magnetic Stimulation (TMS) applied on the left dorsolateral prefrontal cortex in patients with Major Depressive disorder and tobacco consumption.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable major-depressive-disorder

Timeline
Completed

Started Oct 2021

Shorter than P25 for not_applicable major-depressive-disorder

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2021

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 12, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 23, 2023

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2023

Completed
Last Updated

January 23, 2023

Status Verified

January 1, 2023

Enrollment Period

1.2 years

First QC Date

January 12, 2023

Last Update Submit

January 12, 2023

Conditions

Keywords

Transcranial magnetic stimulationTheta BurstDepressionTobaccosuicide ideation

Outcome Measures

Primary Outcomes (18)

  • MINI Neuropsychiatric Interview

    It is a short structured diagnostic interview that explores the main psychiatric disorders of Axis I of DSM-IV and ICD-10

    15 minutes

  • Fagerström test

    it is a short and simple test consisting of 6 questions. The score ranges from 0-10, so that the higher the score, the greater the dependency. Not only does this test measure physical dependence but it also has therapeutic and prognostic value.

    5 minutes

  • Richmond Test

    Scale consisting of 4 items to assess the degree of motivation to quit smoking on a scale of 1 to 10. For an individual to have expectations of success in a smoking cessation program, they must present a score of 9 or 10 points

    5 minutes

  • Glover-Nilsson Test

    Test consisting of 11 items to measure the psychosocial and behavioral dependence of individuals; it is scored from 0 to 4, with 4 being the maximum score, items 1,4 and 5 measure psychological dependence, questions 2,3,6,7,8,9 and 10 measure behavioral dependence and question 11 measures social dependence.

    8 minutes

  • Test of the Unit of the Institute of Public Health of Madrid (UISPM)

    Test consisting of 23 items divided into 6 modules (stimulation, sedation, automatism, social dependency, psychic dependency and gestural dependency) each item is scored from 0 to 4 being 4 the highest score.

    10 minutes

  • Minnesota Nicotine Withdrawal Syndrome Scale (MNWS)

    This eight-item scale measures withdrawal symptoms (craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia), The score ranges from 0 to 4, with 4 being the highest score, indicating a severe withdrawal syndrome

    5 minutes

  • Nicotine Craving Questionnaire (CCN)

    12-item questionnaire to assess the degree of craving, with five response options ranging from completely disagree 1 to completely agree 5

    8 minutes

  • Paradigm of reactivity to signals and heart rate variability

    it consists of presenting a series of images that were chosen from the International Series of images for smoking (with neutral counterparts), Version 1.2 (58), the images were presented as follows : 2 blocks of smoking images and 2 blocks with neutral images that are interspersed, each block contains 25 images with a duration of 6 seconds per image, the test has a total duration of 10 minutes; while the participant observes the images, they will place a polar model H10 bluetooh chest strap sensor to measure HRV

    10 minutes

  • Co-oximetry

    spectrophotometric technique to detect the loss in the oxygenation capacity of hemoglobin that consists of determining the level of carbon monoxide (CO) in the air exhaled by an individual, levels of 10 or more ppm of CO in the exhaled air correspond to smoking subjects. Levels of 6 to 10 ppm in sporadic smokers, and figures below 6 ppm in non-smokers.

    1 minute

  • Hamilton Rating Depression Scale (HDRS)

    21 item, Clinical assessment of depressive symptoms

    10 minutes

  • Montgomery-Asberg Rating Depression Scale (MADRS)

    10 ítem Clinical assessment of the principal depressive symptoms

    10 minutes

  • Hamilton Anxiety Rating Scale (HARS)

    14 Ítem clinical scale for rating anxiety symptoms.

    10 minutes

  • Beck Depression Invetory (BDI)

    it´s a 21 ítem self evaluated symptomatology of depression

    10 minutes

  • Beck Hopelesness Scale (BHS)

    is a 20-item self-report inventory designed to measure 3 major aspects of hopelessness (Feelings about the future, loss of self-motivation and expectations)

    10 minutes

  • Plutchik Risk Suicide Scale

    it´s a 26 ítem self-reported scale that assess the intensity of suicidal ideation

    10 minutes

  • Beck suicidal ideation scale (BSIS)

    is an evaluation of suicidal thinking: is an evaluation of suicidal thinking that helps identify individuals at risk of comitting self harm

    10 minutes

  • Wisconsin Card Sorting Test (WCST)

    is a neuropsychological test that assess cognitive flexibility

    20 minutes

  • Stop Signal Task

    is a unique versión of a classic approach to measuring response inhibition

    25 minutes

Secondary Outcomes (1)

  • Marlowe and Crowne Social Desirability Scale

    10 minutes

Study Arms (2)

1 session

EXPERIMENTAL

Participants will receive 1 session from monday to friday,during 4 weeks, with 600 total pulses per session

Device: Theta Burst Transcranial Magnetic Stimulation

3 sessions

EXPERIMENTAL

Participants will receive 3 sessions from monday to friday,during 4 weeks, with 1800 total pulses per session with a 10 minutes rest interval

Device: Theta Burst Transcranial Magnetic Stimulation

Interventions

Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill

1 session3 sessions

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • With dependence on tobacco use, with depressive symptomatology, that they agree to sign the informed consent letter.

You may not qualify if:

  • History of head trauma with loss of consciousness, with intracranial metallic objects or metallic plates in the skull, patients with structured suicidal ideation or recent attempts, who suffer from uncontrolled chronic diseases at the time of entering the study (for example: hypertension, diabetes, rheumatic diseases), patients with psychotic symptoms. subjects with alterations in electroencephalogram (epileptiform activity), patients with any type of uncontrolled chronic medical or neurological disease, pregnant women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sofia Cañizares Gómez

Querétaro City, Querétaro, 76170, Mexico

RECRUITING

Related Publications (9)

  • Fluharty M, Taylor AE, Grabski M, Munafo MR. The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review. Nicotine Tob Res. 2017 Jan;19(1):3-13. doi: 10.1093/ntr/ntw140. Epub 2016 May 19.

  • Picciotto MR, Mineur YS. Molecules and circuits involved in nicotine addiction: The many faces of smoking. Neuropharmacology. 2014 Jan;76 Pt B(0 0):545-53. doi: 10.1016/j.neuropharm.2013.04.028. Epub 2013 Apr 28.

  • Ahern E, Kinsella S, Semkovska M. Clinical efficacy and economic evaluation of online cognitive behavioral therapy for major depressive disorder: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):25-41. doi: 10.1080/14737167.2018.1407245. Epub 2017 Nov 30.

  • Garcia-Gomez L, Hernandez-Perez A, Noe-Diaz V, Riesco-Miranda JA, Jimenez-Ruiz C. SMOKING CESSATION TREATMENTS: CURRENT PSYCHOLOGICAL AND PHARMACOLOGICAL OPTIONS. Rev Invest Clin. 2019;71(1):7-16. doi: 10.24875/RIC.18002629.

  • Baeken C, Marinazzo D, Everaert H, Wu GR, Van Hove C, Audenaert K, Goethals I, De Vos F, Peremans K, De Raedt R. The Impact of Accelerated HF-rTMS on the Subgenual Anterior Cingulate Cortex in Refractory Unipolar Major Depression: Insights From 18FDG PET Brain Imaging. Brain Stimul. 2015 Jul-Aug;8(4):808-15. doi: 10.1016/j.brs.2015.01.415. Epub 2015 Feb 7.

  • Arikan MK, Gunver MG, Tarhan N, Metin B. High-Gamma: A biological marker for suicide attempt in patients with depression. J Affect Disord. 2019 Jul 1;254:1-6. doi: 10.1016/j.jad.2019.05.007. Epub 2019 May 6.

  • Mahoney JJ 3rd, Hanlon CA, Marshalek PJ, Rezai AR, Krinke L. Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. J Neurol Sci. 2020 Nov 15;418:117149. doi: 10.1016/j.jns.2020.117149. Epub 2020 Sep 20.

  • Filipcic I, Milovac Z, Sucic S, Gajsak T, Filipcic IS, Ivezic E, Aljinovic V, Orgulan I, Penic SZ, Bajic Z. Efficacy, Safety and Tolerability of Augmentative rTMS in Treatment of Major Depressive Disorder (MDD): A Prospective Cohort Study in Croatia. Psychiatr Danub. 2017 Mar;29(1):31-38. doi: 10.24869/psyd.2017.31.

  • Czeisler ME, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, Weaver MD, Robbins R, Facer-Childs ER, Barger LK, Czeisler CA, Howard ME, Rajaratnam SMW. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057. doi: 10.15585/mmwr.mm6932a1.

MeSH Terms

Conditions

Depressive Disorder, MajorSmoking ReductionDepression

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersHealth BehaviorBehaviorSmokingBehavioral Symptoms

Study Officials

  • Julian V. Reyes López, PhD

    Universidad Autónoma de Querétaro

    STUDY DIRECTOR

Central Study Contacts

sofia cañizares Gómez, master

CONTACT

Gerardo Trejo Cruz, master

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Triple blind study
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 12, 2023

First Posted

January 23, 2023

Study Start

October 1, 2021

Primary Completion

December 1, 2022

Study Completion

January 31, 2023

Last Updated

January 23, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations